Bicara Therapeutics Inc. Common Stock
BCAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.19B
Close$
$1.74
91.3% downside
Current Fair Value
91.3% downsideOvervalued by 91.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.19 Billion |
|---|---|
| Enterprise Value | $869.43 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.52 |
| Beta | -0.56 |
| Outstanding Shares | 60,717,041 |
Return
| Return on Equity | -30.61% |
|---|---|
| Return on Assets | -28.42% |
| Return on Invested Capital | -32.99% |
Valuation & Multiples
| P/E Ratio | -8.39 |
|---|---|
| PEG | -15.97 |
| Price to Sales | - |
| Price to Book Ratio | 2.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.12 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.64
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.9220▲ 292.20% |
|---|---|
| Total Calls | 62,800▲ Infinity% |
| Total Puts | 183,500▲ 22.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 130.33%▲ 23.39% |
|---|---|
| Total Invested | $1.40B▲ 38.70% |
| Investors Holding | 154▲ 9.00% |
ESG Score
No data
About Bicara Therapeutics Inc. Common Stock
55 employees
CEO: Ms. Claire Mazumdar Clemon M.B.A., Ph.D. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR)...